TABLE 5 | ||||||||||||||||||||||||
REGENERON PHARMACEUTICALS, INC. | ||||||||||||||||||||||||
NET PRODUCT SALES OF REGENERON-DISCOVERED PRODUCTS (Unaudited) | ||||||||||||||||||||||||
(In millions) | ||||||||||||||||||||||||
Three Months Ended March 31, | ||||||||||||||||||||||||
2019 | 2018 | |||||||||||||||||||||||
U.S. | ROW | Total | U.S. | ROW | Total | |||||||||||||||||||
EYLEA* | $ | 1,074.1 | $ | 669.4 | $ | 1,743.5 | $ | 984.0 | $ | 624.0 | $ | 1,608.0 | ||||||||||||
Libtayo | 26.8 | — | 26.8 | — | — | — | ||||||||||||||||||
ARCALYST | 3.5 | — | 3.5 | 3.9 | — | 3.9 | ||||||||||||||||||
Net product sales recorded by Regeneron | $ | 1,104.4 | $ | 987.9 | ||||||||||||||||||||
Net product sales recorded by Sanofi*: | ||||||||||||||||||||||||
Dupixent | $ | 303.0 | $ | 70.7 | $ | 373.7 | $ | 116.8 | $ | 14.6 | $ | 131.4 | ||||||||||||
Praluent | $ | 22.9 | $ | 41.0 | $ | 63.9 | $ | 31.7 | $ | 28.2 | $ | 59.9 | ||||||||||||
Kevzara | $ | 20.7 | $ | 13.0 | $ | 33.7 | $ | 9.3 | $ | 3.1 | $ | 12.4 | ||||||||||||
ZALTRAP | $ | 0.5 | $ | 24.0 | $ | 24.5 | $ | 2.4 | $ | 23.9 | $ | 26.3 | ||||||||||||
* Bayer records net product sales of EYLEA outside the United States and Sanofi records global net product sales of Dupixent, Praluent, Kevzara, and ZALTRAP. Refer to Table 4 for the Company's share of profits/losses recorded in connection with sales of EYLEA outside the United States and global sales of Dupixent, Praluent, and Kevzara. Sanofi pays the Company a percentage of aggregate net sales of ZALTRAP. |